Findings

What do systematic reviews say?

461 questions · 472 findings · 42 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 93 · 19.7%GRADE not reported 81 · 17.2%Very low 99 · 21%Low 103 · 21.8%Moderate 75 · 15.9%High 21 · 4.4%

Therapeutic ultrasound vs placebo

Long‐term improvement in hand grip strength (six months · patients with CTS

1 finding from 1 review

Therapeutic ultrasound for carpal tunnel syndrome 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Low

Ergonomic keyboard vs placebo

Short‐term overall improvement ‐ not measured · carpal tunnel syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Ergonomic positioning or equipment for treating carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ergonomic keyboard vs placebo

Adverse effects ‐ not measured · carpal tunnel syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Ergonomic positioning or equipment for treating carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ergonomic keyboard vs placebo

Short‐term improvement in CTS symptoms (pain) (3 months or less) ‐ At end of 12 weeks treatment (Protouch Keyboard) Scale: 0 to 10 · carpal tunnel syndrome

1 finding from 1 review

Ergonomic positioning or equipment for treating carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Ergonomic keyboard vs placebo

Functional ability · carpal tunnel syndrome

1 finding from 1 review

Ergonomic positioning or equipment for treating carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Ergonomic keyboard vs placebo

Long‐term improvement in CTS symptoms (pain ) from baseline to end of 6 months treatment (Apple Adjustable Keyboard) Scale: 0 to 10 · carpal tunnel syndrome

1 finding from 1 review

Ergonomic positioning or equipment for treating carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Ergonomic keyboard vs placebo

Improvement in functional ability · carpal tunnel syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Ergonomic positioning or equipment for treating carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

3,4‐Diaminopyridine vs placebo

Muscle strength · participants with Lambert‐Eaton myasthenic syndrome

1 finding from 1 review

Treatment for Lambert‐Eaton myasthenic syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 40 participants
Moderate

3,4‐Diaminopyridine vs placebo

Improvement in mean CMAP amplitude (mV) · participants with Lambert‐Eaton myasthenic syndrome

1 finding from 1 review

Treatment for Lambert‐Eaton myasthenic syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 94 participants
High

3,4‐Diaminopyridine vs placebo

Adverse events · participants with Lambert‐Eaton myasthenic syndrome

1 finding from 1 review

Treatment for Lambert‐Eaton myasthenic syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 42 participants
High

Vaccination vs placebo

Persistence of PHN among all subjects a numerical rating scale for pain1 · people at risk for postherpetic neuralgia

Vaccination leads to lower persistence of PHN among all subjects a numerical rating scale for… compared with placebo (high certainty).

1 finding from 1 review

Vaccination for preventing postherpetic neuralgia 2011 · Cochrane Headline outcomes only
RR 0.31 [0.18, 0.54]
1 study · 38501 participants
High

Vaccination vs placebo

Persistence of PHN among subjects developing herpes zoster a numerical rating scale for pain1 · people at risk for postherpetic neuralgia

Vaccination showed no clear difference in persistence of PHN among subjects developing herpes zoster a… compared with placebo (moderate certainty).

1 finding from 1 review

Vaccination for preventing postherpetic neuralgia 2011 · Cochrane Headline outcomes only
RR 0.64 [0.38, 1.09]
1 study · 957 participants
Moderate

Vaccination vs placebo

Death during whole · people at risk for postherpetic neuralgia

Vaccination showed no clear difference in deaths among all subjects during the whole study clinical compared with placebo (high certainty).

1 finding from 1 review

Vaccination for preventing postherpetic neuralgia 2011 · Cochrane Headline outcomes only
RR 1 [0.91, 1.1]
1 study · 38546 participants
High

Vaccination vs placebo

Serious adverse events among subjects in the adverse event substudy clinical manifestations · people at risk for postherpetic neuralgia

Vaccination leads to higher serious adverse events among subjects in the adverse event substudy… compared with placebo (high certainty).

1 finding from 1 review

Vaccination for preventing postherpetic neuralgia 2011 · Cochrane Headline outcomes only
RR 1.53 [1.03, 2.25]
1 study · 6616 participants
High

Any CNTF vs placebo

Deaths · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Any CNTF showed no clear difference in deaths compared with placebo (high certainty).

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
RR 1.07 [0.81, 1.41]
2 studies · 1300 participants
High

Any CNTF vs placebo

Muscle strength · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1300 participants
High

Any CNTF vs placebo

FVC (% predicted) Change from baseline · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1300 participants
High

Changes in quality of life (SIP) change in Sickness Impact Profile (SIP) scores (range from 0 = best health to 100 = worst health). · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
no estimate extracted
1 study · 503 participants
High

Any CNTF vs placebo

Asthenia · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Any CNTF showed no clear difference in asthenia compared with placebo (high certainty).

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
RR 1.02 [0.81, 1.28]
1 study · 570 participants
High

Any CNTF vs placebo

Nausea · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Any CNTF showed no clear difference in nausea compared with placebo (high certainty).

1 finding from 1 review

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease 2004 · Cochrane Headline outcomes only
RR 1.35 [0.92, 1.99]
1 study · 570 participants
High